Standard of Care for Soft-Tissue Sarcoma

Submitted by admin5 on Thu, 10/26/2017 - 04:09

According to a recent study published in The LANCET Oncology, which treatment option is considered and should remain the standard of care for soft-tissue sarcoma?

-----

A. Gemcitabine

B. Doxorubicin

C. Eribulin 

D. Gemcitabine plus doxorubicin 

-----

To see the correct answer, click here.

 

Related Content

Soft Tissue Sarcoma Differences Might Have Therapeutic Implications

Survivors of Soft-Tissue Sarcoma Face Increased Risk of Hospitalization